These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12014372)

  • 1. CD34 stem cell dose and development of extensive chronic graft-versus-host disease.
    Handgretinger R; Lang P; Klingebiel T; Niethammer D
    Blood; 2002 May; 99(10):3875-6; author reply 3876-7. PubMed ID: 12014372
    [No Abstract]   [Full Text] [Related]  

  • 2. Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.
    Martin PS; Li S; Nikiforow S; Alyea EP; Antin JH; Armand P; Cutler CS; Ho VT; Kekre N; Koreth J; Luckey CJ; Ritz J; Soiffer RJ
    Haematologica; 2016 Apr; 101(4):499-505. PubMed ID: 26768686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.
    Newell LF; Shoop KM; Knight RJ; Murray SN; Kwock RP; Jacoby CE; Slater S; Allen BE; Ottowa C; Cota B; Appel PL; Cook RJ; Maziarz RT; Meyers G
    Cytotherapy; 2019 Jul; 21(7):725-737. PubMed ID: 31085121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic transplantation of peripheral blood progenitor cells.
    Link H; Arseniev L
    Ann Oncol; 1996; 7 Suppl 2():41-5. PubMed ID: 8805948
    [No Abstract]   [Full Text] [Related]  

  • 5. Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.
    Gómez-Almaguer D; Gómez-Peña Á; Jaime-Pérez JC; Gómez-Guijosa MÁ; Cantú-Rodríguez O; Gutiérrez-Aguirre H; Martínez-Cabriales SA; García-Rodríguez F; Olguín-Ramírez LA; Salazar-Riojas R; Méndez-Ramírez N
    J Clin Apher; 2013 Oct; 28(5):349-55. PubMed ID: 23682006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.
    Fujii H; Luo ZJ; Kim HJ; Newbigging S; Gassas A; Keating A; Egeler RM
    PLoS One; 2015; 10(7):e0133216. PubMed ID: 26176698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell dose and differentiation.
    MacDonald KP; Rowe V; Filippich C; Johnson D; Morris ES; Clouston AD; Ferrara JL; Hill GR
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):373-85. PubMed ID: 15148491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developments in allogeneic peripheral blood progenitor cell transplantation.
    Russell NH; Gratwohl A; Schmitz N
    Br J Haematol; 1998 Dec; 103(3):594-600. PubMed ID: 9858206
    [No Abstract]   [Full Text] [Related]  

  • 9. Autologous graft-versus-host disease.
    Hess AD
    J Hematother Stem Cell Res; 2000 Jun; 9(3):297. PubMed ID: 10894350
    [No Abstract]   [Full Text] [Related]  

  • 10. Transplantation of allogeneic rhG-CSF mobilized peripheral CD34+ cells from an HLA-identical unrelated donor.
    Stockschläder M; Löliger C; Krüger W; Zeller W; Heyll A; Schönrock-Nabulsi P; Zander A
    Bone Marrow Transplant; 1995 Nov; 16(5):719-22. PubMed ID: 8547873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk assessment in haematopoietic stem cell transplantation: stem cell source.
    Urbano-Ispizua A
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):265-80. PubMed ID: 17448961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.
    Baron F; Maris MB; Storer BE; Sandmaier BM; Panse JP; Chauncey TR; Sorror M; Little MT; Maloney DG; Storb R; Heimfeld S
    Leukemia; 2005 May; 19(5):822-8. PubMed ID: 15772701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.
    Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB
    Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rigorous administration of methotrexate and outcome of allogeneic blood stem cell transplantation.
    Mehta J; Singhal S
    Bone Marrow Transplant; 2007 Feb; 39(4):243-4. PubMed ID: 17211427
    [No Abstract]   [Full Text] [Related]  

  • 16. Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients with advanced hematologic malignancy.
    Bensinger WI; Buckner CD; Rowley S; Demirer T; Storb R; Appelbaum FA
    Bone Marrow Transplant; 1996 Mar; 17 Suppl 2():S38-9. PubMed ID: 8722333
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of CD34 cell dose on acute graft versus host disease after allogeneic bone marrow stem cell transplantation.
    Damiani D; Sperotto A; Geromin A; Stocchi R; Fanin R
    Leuk Lymphoma; 2002 Nov; 43(11):2245-7. PubMed ID: 12533058
    [No Abstract]   [Full Text] [Related]  

  • 18. Is there an increased risk of graft-versus-host disease after allogeneic peripheral blood stem cell transplantation?
    Koc H; Gürman G; Arslan O; Ozcan M; Akan H; Ilhan O; Konuk N; Beksaç M; Uysal A
    Blood; 1996 Sep; 88(6):2362-4. PubMed ID: 8822963
    [No Abstract]   [Full Text] [Related]  

  • 19. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
    Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and graft characteristics in pediatric hematopoietic stem cell transplantation: Effect of granulocyte-colony stimulating factor priming.
    Fettah A; Özbek N; Azık F; Tavil B; Özgüner M; Avcı Z; Işık P; Yaralı N; Uçkan D; Tunç B
    Transfus Apher Sci; 2015 Jun; 52(3):332-8. PubMed ID: 25779226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.